Darren Dasburg

Chief Executive Officer

Professional Overview

Darren Dasburg is a seasoned biopharmaceutical executive with over 20 years of experience leading strategic initiatives and driving innovation across the industry. As a versatile leader, he has held concurrent Chief Executive Officer, Chief Business Officer, and Vice President roles, leveraging his deep expertise in biopharma manufacturing, CRISPR biotechnologies, and corporate strategy.

Experience Summary

Current Roles

Chief Executive Officer, Clarus Biologics Inc. (Present)

• Responsible for overseeing the company's overall strategic direction, operational management, and commercialization of its novel biologics pipeline.

• Spearheaded the successful development and regulatory approval of the company's lead therapeutic candidate, a first-in-class biologic for the treatment of a rare genetic disorder.

• Secured significant venture funding and strategic partnerships to accelerate Clarus Biologics' growth and expand its product portfolio.

Chief Business Officer, CRISPR Biotechnologies/Ancilia Biosciences (Present)

• Drives the company's business development strategy, including identifying and negotiating strategic partnerships, licensing agreements, and merger and acquisition opportunities.

• Oversees the integration of CRISPR Biotechnologies and Ancilia Biosciences, leveraging synergies to enhance the company's gene editing capabilities and therapeutic pipeline.

• Serves as a key member of the executive team, contributing to the overall strategic vision and positioning of the combined entity.

Chief Executive Officer, TREECO (an Outset company) (Present)

• Leads the strategic direction and operational management of TREECO, an Outset company focused on developing sustainable biobased materials and chemicals.

• Spearheads the company's research and development efforts, collaborating with a multidisciplinary team to create innovative, eco-friendly solutions for various industries.

• Secures funding and strategic partnerships to accelerate TREECO's growth and commercialization of its proprietary technologies.

Previous Experience

Vice President, PMO/Strategy Team, AstraZeneca (Past)

• Directed the Project Management Office and led the development of the company's strategic initiatives, driving cross-functional collaboration and alignment.

• Implemented robust project management frameworks and data-driven decision-making processes to optimize the company's R&D pipeline and operational efficiency.

• Played a pivotal role in the successful integration of acquisitions and the implementation of organizational restructuring initiatives.

Vice President, Biopharma Manufacturing, MedImmune (Past)

• Oversaw the design, construction, and commissioning of a state-of-the-art biopharmaceutical manufacturing facility, ensuring compliance with regulatory standards and industry best practices.

• Developed and implemented innovative manufacturing processes to enhance productivity, reduce costs, and improve quality control.

• Led a team of experienced professionals and fostered a culture of continuous improvement and operational excellence.

Academic Background

Darren holds a Bachelor of Science degree in Chemical Engineering from the University of North Carolina at Chapel Hill, where he graduated with honors.

Areas of Expertise

• Biopharmaceutical manufacturing and process development

• CRISPR-based gene editing technologies

• Corporate strategy and business development

• Project management and operational excellence

• Mergers, acquisitions, and integration

• Sustainable materials and green chemistry

Professional Impact

• Instrumental in the successful development and commercialization of multiple biologic products, including a first-in-class therapy for a rare genetic disorder.

• Played a key role in the integration and growth of CRISPR Biotechnologies and Ancilia Biosciences, leveraging synergies to enhance the company's gene editing capabilities.

• Spearheaded the development and implementation of innovative manufacturing processes and sustainability initiatives, contributing to improved productivity, cost-effectiveness, and environmental responsibility.

• Recognized as a thought leader in the biopharmaceutical industry, frequently invited to speak at industry conferences and events.

Conclusion

With his extensive experience, strategic vision, and proven track record of driving innovation and operational excellence, Darren Dasburg is poised to continue making significant contributions to the biopharmaceutical and sustainable materials industries. His multifaceted expertise and collaborative leadership style position him as a valuable asset in shaping the future of these dynamic and rapidly evolving sectors.